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Cancer is a disease of uncontrolled genera�on of cells based off the loss of func�on of tumor sup-
pressor genes or gain of func�on of oncogenes. This disease can proliferate in any �ssues in the body, 
including neural �ssues such as the brain of which is one of the most invasive types. Glioblastoma 
mul�forme (GBM), a malignancy of the suppor�ng cells of the brain, is one of the most aggressive 
forms of brain cancers. With a median survival of only 14.6 months, the bleak prognosis of GBM is a 
result of the high rate of recurrence in pa�ents. (1,3) When an individual is diagnosed with GBM, de-
pending on the loca�on of the tumor, there are three treatment op�ons. These include surgery, radi-
a�on, chemotherapy or the combina�on of these treatments. If the pa�ent decides to go through 
with chemotherapy for treatment; there is a high probability of intense damage done on the body in 
response to the treatment. Usually this type of treatment has a well-received response by the shrink-
ing or elimina�ng of the tumor all  together depending on the case.
Based off this informa�on, some ques�ons we asked before to help lead our research was: What is caus-
ing escala�on in expression of this enzyme? Is this escala�on directly correla�ng in response to TMZ? If 
so, is the increase in enzyme ac�vity dose dependent? If not, does this occur naturally in GBM cells and 
is there a way to inhibit these enzymes while administering chemotherapy to make it more effec�ve?
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Figure 2. According to the IMPDH specific activity data, around hour 48 
there seems to be an increase in activity in response to TMZ treatment. 
DMSO and TMZ treated have some correlation towards the end of collec-
tion. Going further with the project it was decided to run kinetic activity 
assay in order to get a better understanding of what was happening during 
the duration of the incubation.
Figure 3. According to another trial of the IMPDH specific data, around 
hour 24 there seems to be an increase in activity in response to TMZ 
treatment. DMSO and TMZ treated have some correlation towards the 
end of collection.
Figure 4.  According to the absorbance activity, IMPDH in the TMZ 
condition initially is at a high level but linearly decreases and pla-
teaus around the same level as DMSO and the control by the end of 
2 hours.
Figure 5. According to the absorbance activity,  IMPDH activity for TMZ was 
now seen initially at a lower level, jumping further along and then plateauing 
around the same level as DMSO and the control by 2 hours elapsed time.
Figure 6. By 48 hours post-treatment, TMZ’s IMPDH activity is near 
baseline levels compared to control and DMSO timepoints.
Figure 7. By 96 hours post-treatment, the DMSO and TMZ conditions are 
indistiguishable, either implying that TMZ is used up or that the effect of 
TMZ on IMPDH is completed
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Abstract
Glioblastoma mul�forme (GBM), a malignancy of the glioblast stem cells of the brain, is one of the 
most aggressive and untreated forms of brain cancer. When an individual is diagnosed with GBM, de-
pending on the loca�on of the tumor, there are three treatment op�ons including surgery, radia�on, 
chemotherapy or the combina�on of these treatments. Many pa�ents choose chemotherapy, how-
ever most GBM cases show li�le to no response to Temozolomide (TMZ), which is a common chemo-
therapy drug used for this type of cancer. In some recent studies, researchers have no�ced an elevat-
ed amount or over produc�on of an enzyme, Inosine 5'-monophosphate dehydrogenase (IMPDH). 
This enzyme helps with DNA repair but in many GBM cases, due to its over produc�on, it repairs at 
such a fast rate it does not allow TMZ to terminate the cancerous tumors. In our research we have 
been inves�ga�ng whether the chemotherapeu�c agent causes the increase in expression directly or 
whether it is a unique property of this cell type. Future direc�ons involve: determining a molecular 
pathway that could lead to IMPDH expression at such high levels under chemotherapeu�c stress and 
whether co-administering IMPDH inhibitors with TMZ can improve prognosis for those suffering from 
GBM.
Figure 1. A. human brain affected with glioblastoma mul�forme. An obvious tumor mass is observed. B-C. Human U251 GBM cell lines used in this study.
D. Temozolomide (TMZ) alkylates DNA on guanine  residues and suppresses the ability for the DNA to divide, hal�ng the cancer. E. Common events in the 
treatment of GBM with TMZ leading to our hypothesis that IMPDH increases specifically in reponse to TMZ treatment.   F. Role oF IMPDH In purine 
biosynthesus. G. Flowchart of experimenta�on to determine IMPDH ac�vity change during treatment
A
D Patient has GBM and is treated with TMZ
As exposure to TMZ is 
increased, enzyme 
activity would respond 
Hypothesis
Increased activity results in cell proliferation 
and any DNA damage TMZ has done to the 
tumor has been reversed
TMZ tries to repress the tumor’s DNA
by methylating at guanine residues
The tumor is relatively unaffected 
by the chemotherapy and continues 
to metastasize
IMPDH, the enzyme responsible for 




Seed Cells in SIM+FBS Treat cells with TMZ (treatment) or 
DMSO (control)
Harvest cells at 6, 24, 48, 96 hours post treatment and perform IMPDH assay  
and Bradford assay to determine specific ac�vity of IMPDH as a func�on 
of treatment �me
F G
TMZ treated U251 GBM cells do not appear to  deviate from the control treatment overall but may exhibit spikes of ac�vity a�er treatment, which reverts to baseline 
within 24 hours. We are currently working on determining why the �ming may vary based on our experimental condi�ons. 
Experimental setup at each �mepoint: 
Cells are washed, trypsinized and resuspended in cold PBS Cells are spun down and  chemically lysed 
Cell lysate is incubated with assay reagents 
for 2 hours at 37C & measured for protein
concentra�on. Absorbance of assay is read. 
Problem: A 2 hour assay followed by an absorbance measurement doesn’t give us very good resolu�on on what is happening 
in the assay during the incuba�on. Perhaps the assay doesn’t reveal the whole story in the way we are doing it.
Approach: Perform assay in microplate reader to determine what is happening in the assay in real-�me.
Based off the data collected, it was determined that TMZ has some sort of 
influence on IMPDH activity levels. Simplistically looking at the kinetic 
graphs, the longer exposure of TMZ the cells have, the more similar the 
kinetic curves seem to be. Overall, the analyzed data collected was some-
what inconclusive but there are evident changes being seen. More trials 
are being done and data is being analyzed to help develop a more conclu-
sive understanding.
The future direction of the project includes optiizing our assay and 
using different lines of GBM to determine enzyme activities in cor-
relation to the cell line used for this project. In addition, there is 
some interest in working with different types of cancer lines as well 
as HeLa cells to see how the results would correlate. In addition, 
some studies have shown that an IMPDH inhibitor drug, Mycophe-
nolate Mofetil (MMF), has been approved as an anti-tumor effects in 
solid and blood cancers of which could be used in our lab in a cock-
tail with TMZ and see the correlating effects on cell line proliferation 
Figure 8. A. Mycophenolate, an IMPDH inhibitor 
drug that could be co-treated with TMZ to 
enhance prognosis and outcomes. 
B. Mycophenolate blocks IMPDH activity, leading
to a defective de novo guanine synthesis pathway  
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